AP Pharma completes enrollment in Phase III CINV trial

Jun 24, 2008 (Datamonitor via COMTEX) -- APPAD | Quote | Chart | News | PowerRating -- AP Pharma has completed patient enrollment in its pivotal Phase III study in chemotherapy-induced nausea and vomiting comparing the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting in both moderate and highly emetogenic chemotherapy treatments.

The trial is being conducted in the US, India and Poland. Data collection will be finalized following completion of treatment of the last patients, expected near the end of July 2008.

The results of the trial will be announced following the unblinding of data, which is anticipated to occur late in the third quarter of 2008.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index